Johnson & Johnson Announces $2.2 Billion Ollin Biosciences Acquisition to Add Phase 3 Eye Antibody OLN324
Johnson & Johnson has agreed to acquire Ollin Biosciences for $2.2 billion upfront, adding the Phase 3 bispecific antibody OLN324 for wet AMD and diabetic macular edema. A separate $750 million Blackstone Life Sciences funding agreement would support Phase 3 development.
